奥美沙坦酯与吲哒帕胺联合治疗原发性高血压的疗效观察

Olmesartan Medoxomil Combined with Indapamide Efficacy of Treatment of Essential Hypertension

目的:探讨奥美沙坦酯联合吲哒帕胺在原发性高血压治疗中的临床应用价值。方法:226例原发性高血压患者随机分为对照组和观察组各113例,对照组给予对照组贝那普利联合吲哒帕胺治疗;观察组给予美沙坦酯联合吲哒帕胺治疗,观察两组患者的有效率、收缩压(SBP)、舒张压(DBP)、谷峰比值、不良反应,进行对比分析。结果:两组患者的有效率、SBP、DBP、谷峰比值差异不明显(P>0.05);观察组不良反应发生率明显低于对照组(P<0.05)。结论:在原发性高血压治疗中,奥美沙坦酯联合吲哒帕胺治疗是一种安全、有效的治疗方法,见效快、不良反应少。

Objective：To explore olmesartan medoxomil combined indapamide in the treatment of essential hypertension clinical value. Methods：226 cases of patients with essential hypertension were randomly divided into control group and observation group of 113 cases in the control group were given benazepril combined with indapamide therapy;observation group were given America medoxomil combined indapamide treatment, observation Both groups were efficient, systolic blood pressure （SBP）, diastolic blood pressure （DBP）, trough to peak ratios, adverse reactions were analyzed. Results：Both groups were efficiency, SBP, DBP, trough to peak ratio was not significantly different（P〈0.05）;incidence of adverse reactions observed group was significantly lower than the control group（P〈0.05）. Conclusions：In the treatment of essential hypertension, olmesartan medoxomil combined indapamide therapy is a safe and effective treatment, quick, fewer adverse reactions.